Skip to main content

Psoriasis News

A study found that a majority of women in the Nurses' Health Study II (NHS II) with psoriasis had mild disease, and that a large proportion of these patients were diagnosed by providers other than dermatologists.
A Medicare claims-based algorithm using both psoriasis diagnosis codes and PsO-specific treatment dispensing had a significant positive predictive value for identifying patients with psoriasis effectively.
A recent study aimed to evaluate whether early Psoriasis Area Severity Index (PASI) improvements can predict week 28 tildrakizumab responders and nonresponders.
A study published in Journal of Drugs in Dermatology described the outcomes of two phase 3 trials that demonstrated the efficacy and safety of halobetasol propionate (HP) 0.01% lotion in the treatment of moderate to severe plaque psoriasis.
A study was conducted to estimate health care resource utilization (HCRU) in addition to economic burden of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) in a commercially insured population the United States.
A study published in Journal of the American Academy of Dermatology aimed to compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and benefit-risk profiles of moderate to severe plaque psoriasis treatments.
A survey found that there are key features within generalized pustular psoriasis (GPP) flares that could launch discussions around consensus guidelines for diagnosis and management.
A study published in Dermatology aimed to characterize patients with vs without psoriasis in challenging-to-treat areas seen in routine US clinical practices as they noted real-world studies are limited.
A prospective, cross-sectional, multicenter study investigated the vascular status of the macula in patients with psoriasis who showed no prior history of ocular inflammation using Optical Coherence Tomography Angiography (OCTA).
Recent assessment has concluded that an increased risk of heart failure is linked to a combination of cardiovascular risk factors as well as onset of disease activity, particularly in nonischemic heart failure.
Back to Top